INCRUSE ELLIPTA Rx
Generic Name and Formulations:
Umeclidinium 62.5mcg; per inhalation; dry pwd for oral inhalation; contains lactose.
Indications for INCRUSE ELLIPTA:
Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
Take at same time every day. 1 inhalation every 24hrs.
Severe hypersensitivity to milk proteins.
Not indicated for relief of acute bronchospasm. Do not initiate in rapidly or acutely deteriorating COPD. Do not exceed recommended dose. Reevaluate periodically. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Discontinue if paradoxical bronchospasm (use alternatives) or hypersensitivity reactions occur. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Severe hepatic impairment. Labor and delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Additive effects with concomitant other anticholinergic-containing drugs; avoid.
Nasopharyngitis, URTI, cough, arthralgia; visual disturbances, paradoxical bronchospasm.
Dry pwd inhaler—30 doses
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Computerized Training Programs for Schizophrenia Improve Cognitive Functioning
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Cost-Effective Telehealth Alternatives for Veterans With Depression
- Polygenic Risk Scores Could Aid in Identifying Bipolar Disorder, Schizophrenia
- Brief Impression Questionnaire Useful in Schizophrenia Diagnoses